---
title: Antibiotics Against Amyloid Angiopathy
nct_id: NCT05680389
overall_status: UNKNOWN
phase: PHASE1, PHASE2
sponsor: Leiden University Medical Center
study_type: INTERVENTIONAL
primary_condition: Cerebral Amyloid Angiopathy
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05680389.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05680389"
ct_last_update_post_date: 2023-01-11
last_seen_at: "2026-05-12T06:50:28.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Antibiotics Against Amyloid Angiopathy

**Official Title:** Placebo-controlled, Randomized, Double-blind Study of Minocycline for Sporadic and Hereditary Cerebral Amyloid Angiopathy

**NCT ID:** [NCT05680389](https://clinicaltrials.gov/study/NCT05680389)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Leiden University Medical Center
- **Conditions:** Cerebral Amyloid Angiopathy
- **Start Date:** 2020-12-02
- **Completion Date:** 2023-12-02
- **CT.gov Last Update:** 2023-01-11

## Brief Summary

We will perform a randomized clinical trial with minocycline. Minocycline is an antibiotic of the tetracycline family and known to modulate inflammation, gelatinase activity and angiogenesis, which we know are central mechanisms in CAA-pathology. Our aim is to prove in a randomized clinical trial in a translational setting that minocycline treatment (duration 3 months) can decrease markers of neuroinflammation and the gelatinase pathway in the cerebrospinal fluid (CSF) of persons with D-CAA (n=30) and sporadic-CAA (n=30).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥18 years for D-CAA and age ≥55 years for sporadic-CAA
* Probable-CAA according to the Modified-Boston-Criteria or genetically proven D-CAA
* ≤ 2 ICH (occurrence of ICHs at least 1 year ago) and presence of ≥ 2 lobar microbleeds +/-cortical superficial siderosis
* Written informed consent

Exclusion Criteria:

* Previous allergic reactions to minocycline
* Modified Rankin Score ≥3
* Contraindications, such as:
* Contraindications for 7T MRI as determined by the 7Tesla safety committee. Examples of possible contra-indications are: claustrophobia, pacemakers and defibrillators, nerve stimulators, intracranial clips, intraorbital or intraocular metallic fragments, cochlear implants, ferromagnetic implants, hydrocephalus pump, intra-uterine device, permanent make-up, tattoos above the shoulders. In case of specific contra-indications for 7T a 3T will be made instead. - Specific contraindications for checkerboard fMRI: seizure within prior year, photosensitive epilepsy, noncorrectable visual impairment. - Contraindications for lumbar puncture: compression of the spinal cord, signs and symptoms of increased intracranial pressure, local infections of the skin at the puncture site, a coagulopathy or thrombocytopenia (\<100). (Use of acetylsalicylic acid, NSAIDs, COX2 inhibitors or low-molecular-weight heparin are no contraindications for lumbar puncture.)
* Pregnancy/breast feeding
* Liver/renal failure
* Use of antibiotics \<1 month
* SLE or other diseases known to generate inflammatory responses
* Previous/current/planned use of retinoids (since this is related to increasing risk of increased intracranial pressure)
* Current use of anaesthetics like methoxyflurane, agents inhibiting peristalsis, barbiturates, carbamazepine or fenytoïne
```

## Arms

- **Minocycline** (EXPERIMENTAL) — 100 mg twice daily for 3 months
- **Placebo** (PLACEBO_COMPARATOR) — twice daily for 3 months

## Interventions

- **Minocycline** (DRUG) — 100 mg twice daily for 3 months
- **Placebo** (DRUG) — twice daily for 3 months

## Primary Outcomes

- **inflammatory, vessel integrity and gelatinase pathway associated biomarkers in CSF** _(time frame: 3 months)_ — IL6, MCP-1, IBA-1, MMP2/9, and VEGF

## Secondary Outcomes

- **safety and tolerability of minocycline** _(time frame: 3 months)_
- **progression of hemorrhagic markers on 7T MRI before and after treatment** _(time frame: 3 months)_

## Locations (1)

- Leiden University Medical Center, Leiden, Netherlands — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.leiden university medical center|leiden||netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05680389.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05680389*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*